SSY GROUP (02005): Pibedil has been approved by the National Medical Products Administration (NMPA) for registration as an active pharmaceutical ingredient for use in marketed formulations.
Shi Si Yao Group (02005) announced that their product Pibedil has been approved for registration by the China National Medical Products Administration.
SSY GROUP (02005) announced that the group's Pibedil has been approved by the China National Medical Products Administration as a raw material for use in marketed formulations, making it the third domestic company to receive approval. Pibedil is mainly used for the treatment of Parkinson's disease and circulatory disorders.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
